摘要
Background:KRAS p.G12C mutation occurs in approximately 1 to 2%of pancreatic cancers.The safety and efficacy of sotorasib,a KRAS G12C inhibitor,in previously treated patients with KRAS p.G12C-mutated pancreatic cancer are unknown.Methods:We conducted a single-group,phase 1-2 trial to assess the safety and efficacy of sotorasib treatment in patients with KRAS p.G12C-mutated pancreatic cancer who had received at least one previous systemic therapy.
出处
《四川生理科学杂志》
2022年第12期2100-2100,共1页
Sichuan Journal of Physiological Sciences
